Celgene International Sárl Release: Evaluation of REVLIMID(R) in Patients with Either GCB or Non-GCB Diffuse Large B-Cell Lymphoma Presented at American Society of Clinical Oncology

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ:CELG) today announced researchers at the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma (DLBCL) either with a germinal center B-cell (GCB) or non-germinal center B-cell (non-GCB) phenotype.